Tag Archives: AQXP

Best Safest Stocks To Watch For 2019

Conventional wisdom suggests that investors should find safe stocks to buy. Penny stocks and potential “triple-baggers” might be more exciting and a big win might provide a better story, but experts will tell you the smart play is to benefit from compounding returns in safe, stable stocks.

That general strategy is similar to that followed by Warren Buffett with Berkshire Hathaway Inc. (NYSE:BRK.A, NYSE:BRK.B), for instance. Buffett looks for “forever stocks,” with a portfolio that ranges from key parts of the industrial supply chain to consumer brands like The Coca-Cola Co (NYSE:KO) and Dairy Queen. Investors following that type of strategy — again, so the conventional wisdom goes — should benefit from lower volatility and larger returns over time.

Of course, there are a couple of problems with this advice.

The first is that choosing safe stocks to buy is much harder than Buffett himself has made it look. General Motors Company (NYSE:GM) was considered a “widows and orphans” stock for decades — and it went bankrupt in 2008. Investors in 1985 could have argued Dow Jones component companies Eastman Kodak Company (NYSE:KODK), GM, and Sears Holdings Corp (NASDAQ:SHLD) were among the safest plays in the market.

Best Safest Stocks To Watch For 2019: CarMax Inc(KMX)

Advisors’ Opinion:

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage gain ahead of the close CarMax, Inc. (NYSE: KMX) which traded up about 13% at $80.19. The stock’s 52-week range is $57.05 to $81.67. Volume was nearly 12 million compared to the daily average volume of 1.8 million.

  • [By Ethan Ryder]

    Media coverage about CarMax (NYSE:KMX) has been trending somewhat positive on Saturday, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CarMax earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.9476088816755 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

  • [By Rich Smith]

    CarMax (NYSE:KMX) stock is trading near its highs of the day, up 14.2% as of 2:45 p.m. EDT, after the used car specialist reported fiscal Q1 2018 earnings results this morning.

  • [By Garrett Baldwin]

    Get an exclusive invitation to meet Tim before everyone else right here.

    The Top Stock Market Stories for Wednesday
    The U.S. markets are preparing for the eighth interest rate hike since 2015, and the Federal Reserve may not be done yet. Markets are weighing the possibility that the Fed may raise rates one more time this year (in December). The hikes come as the Fed is attempting to shrink its $4.5 trillion balance sheet. When Powell speaks this afternoon, expect a few questions about the impact of the trade war between the United States and China. Reporters will also likely want to know about geopolitical risks to the U.S. economy and how they might affect growth in a higher-interest-rate environment. Yesterday, U.S. President Donald Trump gave a speech before the United Nations General Assembly. During his talk, Trump praised the U.S. economy and defended his administration’s actions this year on trade. Trump said that the United States will no longer endure “abuse” from other trade partners. The U.S. Trade Representative Robert Lighthizer also said Tuesday that the U.S. is prepared to proceed on a new trade deal with Mexico without the participation of Canada. Oil prices are in focus after President Trump called out OPEC members before the U.N. on Tuesday. During his talk, Trump accused OPEC and non-OPEC participants in collusion efforts on production and prices of ripping off the rest of the world.
    Three Stocks to Watch Today: NKE, SVMK, DB
    Shares of Nike Inc. (NYSE: NKE) fell 3.5% after the sports apparel giant reported earnings after the bell. The company topped earnings expectations and reported profit growth of 15%. However, investors took some profits off the table. Shares of Nike stock are up more than 35% on the year. SVMK, the parent company of SurveyMonkey, has priced its upcoming IPO at $12 per share. That figure is above analysts’ initial range expectation of $9 to $11 per share. The firm expects to reach a market capitalization of $1.46 bil

  • [By Trey Thoelcke]

    CarMax Inc. (NYSE: KMX) is set to release its most recent quarterly results first thing on Wednesday. The consensus forecast calls for $0.88 in EPS and $4.21 billion in revenue for the fiscal fourth quarter. Shares traded on Thursday’s close at $61.94. The consensus price target is $77.71, and the 52-week range is $54.29 to $77.64.

Best Safest Stocks To Watch For 2019: Hovnanian Enterprises Inc(HOVNP)

Advisors’ Opinion:

  • [By Logan Wallace]

    News stories about HOVNAN 1000 DS REP 1 SRS A PRF (NASDAQ:HOVNP) have trended positive on Thursday, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. HOVNAN 1000 DS REP 1 SRS A PRF earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.0490974987129 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Best Safest Stocks To Watch For 2019: Aquinox Pharmaceuticals, Inc.(AQXP)

Advisors’ Opinion:

  • [By Steve Symington]

    Still, some individual companies fared worse than most. Read on to learn why Sonic Corporation (NASDAQ:SONC), National Beverage (NASDAQ:FIZZ), and Aquinox Pharmaceuticals (NASDAQ:AQXP) plunged today.

  • [By Paul Ausick]

    Aquinox Pharmaceuticals Inc. (NASDAQ: AQXP) dropped about nearly 85% Wednesday to post a new 52-week low of $2.25. Shares closed at $15.31 on Tuesday and the stock’s 52-week high is $16.90. Volume totaled 13.5 million shares compared to a daily average of less than 200,000. The company’s bladder pain drug failed a trial and the company is stopping development.

  • [By Max Byerly]

    Shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) have received an average recommendation of “Buy” from the seven research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $25.25.

  • [By Chris Lange]

    Aquinox Pharmaceuticals Inc. (NASDAQ: AQXP) saw its shares crash on Wednesday after the firm gave a disappointing update for a late-stage trial. Unfortunately, the firm’s Phase 3 LEADERSHIP 301 clinical trial evaluating rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain syndrome failed to meet its primary endpoint.

  • [By Ethan Ryder]

    Cantor Fitzgerald reiterated their neutral rating on shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) in a research report report published on Wednesday, MarketBeat.com reports.

  • [By Logan Wallace]

    Aquinox Pharmaceuticals (NASDAQ:AQXP) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Monday.

Best Safest Stocks To Watch For 2019: 58.com Inc.(WUBA)

Advisors’ Opinion:

  • [By Shane Hupp]

    58.com Inc (NYSE:WUBA) has been assigned an average rating of “Buy” from the ten research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $78.20.

  • [By Stephan Byrd]

    Shares of 58.com Inc (NYSE:WUBA) have been assigned a consensus rating of “Buy” from the seven brokerages that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $92.00.

  • [By Logan Wallace]

    58.com (NYSE:WUBA) was downgraded by TheStreet from a “b-” rating to a “c+” rating in a research report issued on Thursday.

Best Safest Stocks To Watch For 2019: Blackrock Capital and Income Strategies Fund Inc(CII)

Advisors’ Opinion:

  • [By Stephan Byrd]

    News headlines about BlackRock Enhanced Capital and Income Fd (NYSE:CII) have trended positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. BlackRock Enhanced Capital and Income Fd earned a news sentiment score of 0.31 on Accern’s scale. Accern also assigned media headlines about the real estate investment trust an impact score of 47.3179811195894 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Top 5 Clean Energy Stocks To Own For 2019

If you’re looking to invest in renewable power stocks, you can always pick out pure plays that take advantage of the huge demand for clean energy — and with utility customers inking long-term power contracts as they switch from dirty carbon-based fuels, that might be a winning strategy. However, what if the growth story behind renewables doesn’t live up to today’s hype?

That uncertainty is why a diversified company like NextEra Energy, Inc. (NYSE:NEE), with utility and renewable power operations, might make more sense for conservative investors.

Focusing on renewables

There’s no question that a company like Brookfield Renewable Partners L.P. (NYSE:BEP) is a great direct play on renewable power. Roughly 80% of the company’s power is hydroelectric, with the rest made up largely of wind and solar. Moreover, it has exposure to Brazil (20% of generation) and Columbia (15%), in addition to the United States (60%). Much of the company’s growth has come from acquisitions, and long-term contracts back up the bulk of its revenues. It’s a perfectly fine renewable power investment.

Top 5 Clean Energy Stocks To Own For 2019: Aquinox Pharmaceuticals, Inc.(AQXP)

Advisors’ Opinion:

  • [By Paul Ausick]

    Aquinox Pharmaceuticals Inc. (NASDAQ: AQXP) dropped about nearly 85% Wednesday to post a new 52-week low of $2.25. Shares closed at $15.31 on Tuesday and the stock’s 52-week high is $16.90. Volume totaled 13.5 million shares compared to a daily average of less than 200,000. The company’s bladder pain drug failed a trial and the company is stopping development.

  • [By Logan Wallace]

    Aquinox Pharmaceuticals (NASDAQ:AQXP) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Monday.

  • [By Ethan Ryder]

    Cantor Fitzgerald reiterated their neutral rating on shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) in a research report report published on Wednesday, MarketBeat.com reports.

  • [By Max Byerly]

    Shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) have received an average recommendation of “Buy” from the seven research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $25.25.

Top 5 Clean Energy Stocks To Own For 2019: Exelixis, Inc.(EXEL)

Advisors’ Opinion:

  • [By Max Byerly]

    BidaskClub upgraded shares of Exelixis (NASDAQ:EXEL) from a strong sell rating to a sell rating in a report released on Friday.

    EXEL has been the subject of a number of other research reports. Cann restated a buy rating and set a $40.00 price objective on shares of Exelixis in a research note on Wednesday, May 30th. ValuEngine lowered Exelixis from a sell rating to a strong sell rating in a research note on Friday, May 11th. William Blair reaffirmed a buy rating on shares of Exelixis in a report on Wednesday, April 11th. Oppenheimer raised Exelixis from a market perform rating to an outperform rating and set a $40.00 target price on the stock in a report on Tuesday, February 27th. Finally, Stifel Nicolaus reduced their target price on Exelixis from $30.00 to $29.00 and set a hold rating on the stock in a report on Thursday, May 3rd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $32.80.

  • [By Ethan Ryder]

    Exelixis (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 20,000 shares of the company’s stock in a transaction dated Friday, May 4th. The stock was sold at an average price of $22.36, for a total transaction of $447,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

  • [By Shane Hupp]

    Old Mutual Global Investors UK Ltd. raised its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 26.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,562,369 shares of the biotechnology company’s stock after purchasing an additional 747,398 shares during the quarter. Old Mutual Global Investors UK Ltd. owned 1.20% of Exelixis worth $78,906,000 as of its most recent SEC filing.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    MDC Partners Inc. (NASDAQ: MDCA) fell 23.4 percent to $5.25 in pre-market trading after a first-quarter earnings miss.
    Hudson Technologies Inc. (NASDAQ: HDSN) shares fell 15.1 percent to $3.48 in pre-market trading after the company reported downbeat Q1 earnings.
    Nuance Communications, Inc. (NASDAQ: NUAN) fell 14 percent to $13.15 in pre-market trading after the company posted downbeat Q2 earnings and lowered FY18 organic growth guidance.
    Myomo, Inc. (NYSE: MYO) fell 13.2 percent to $3.10 in pre-market trading after reporting downbeat quarterly results.
    Rowan Companies plc (NYSE: RDC) shares fell 10.7 percent to $14.13 in pre-market trading after climbing 8.50 percent on Wednesday.
    BT Group plc (NYSE: BT) fell 9 percent to $14.80 in pre-market trading after the company reported Q4 results and announced plans to cut 13,000 jobs over the next three years.
    Exelixis, Inc. (NASDAQ: EXEL) fell 8.3 percent to $19.90 in pre-market trading after the company disclosed that IMblaze370 Phase 3 pivotal trial of atezolizumab and cobimetinib in patients with heavily pretreated locally advanced or metastatic colorectal cancer did not meet primary endpoint.
    Infinera Corporation (NASDAQ: INFN) fell 8.2 percent to $10.80 in pre-market trading after reporting Q1 results.
    Synaptics, Incorporated (NASDAQ: SYNA) shares fell 7.4 percent to $43.00 in pre-market trading. Synaptics reported better-than-expected earnings for its third quarter, while sales missed estimates.
    Randgold Resources Limited (NASDAQ: GOLD) shares fell 7.4 percent to $76.23 in pre-market trading after reporting Q1 earnings.
    Integra LifeSciences Holdings Corporation (NASDAQ: IART) shares fell 7 percent to $59.36 in pre-market trading. Integra LifeSciences priced its 5.25 million share public offering of common stock at $58.50 per share.
    Array BioPharma Inc. (NASDAQ: ARRY) shares fell 6.9 percent to $12.75 in pre-m

  • [By Ethan Ryder]

    Exelixis (NASDAQ:EXEL) – Investment analysts at William Blair raised their FY2018 earnings per share (EPS) estimates for shares of Exelixis in a research report issued to clients and investors on Thursday, May 3rd. William Blair analyst A. Hsieh now anticipates that the biotechnology company will post earnings per share of $0.90 for the year, up from their previous estimate of $0.66. William Blair currently has a “Buy” rating on the stock. William Blair also issued estimates for Exelixis’ Q1 2019 earnings at $0.23 EPS, Q2 2019 earnings at $0.25 EPS, Q3 2019 earnings at $0.27 EPS and Q4 2019 earnings at $0.29 EPS.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Exelixis (EXEL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Clean Energy Stocks To Own For 2019: Communications Systems Inc.(JCS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Cara Therapeutics, Inc. (NASDAQ: CARA) shares surged 42.76 percent to close at $16.56 on Wednesday in reaction to a new licensing agreement with Europe-based Vifor Pharma. As part of the agreement, the biopharmaceutical company that alleviates pain licensed worldwide rights (except U.S., Japan, and South Korea) to Vifor Pharma to commercialize its KORSUVA therapy to Vifor $70 million.
    Yangtze River Port and Logistics Limited (NASDAQ: YRIV) gained 31.28 percent to close at $7.05 on Wednesday.
    Tiffany & Co. (NYSE: TIF) climbed 23.29 percent to close at $126.05 after the company reported upbeat results for its first quarter and raised its FY2018 earnings guidance.
    EVO Payments, Inc. (NASDAQ: EVOP) gained 18.88 percent to close at $19.02. EVO Payments priced its IPO at $16 per share.
    Carver Bancorp, Inc. (NASDAQ: CARV) rose 16.1 percent to close at $6.85.
    USA Technologies, Inc. (NASDAQ: USAT) gained 15.68 percent to close at $13.65 after announcing pricing of public offering.
    eXp World Holdings, Inc. (NASDAQ: EXPI) shares jumped 15.01 percent to close at $17.70.
    Geron Corporation (NASDAQ: GERN) gained 14.99 percent to close at $4.68.
    Evolus, Inc. (NASDAQ: EOLS) rose 14.62 percent to close at $19.36.
    Ralph Lauren Corporation (NYSE: RL) shares rose 14.34 percent to close at $133.33 after the company reported stronger-than-expected results for its fourth quarter.
    Turtle Beach Corporation (NASDAQ: HEAR) jumped 13.26 percent to close at $17.34 on Wednesday. Turtle Beach S-3 showed registration for 1.857 million share common stock offering via selling holders.
    Communications Systems, Inc. (NASDAQ: JCS) rose 13.18 percent to close at $3.95. Communications Systems reported establishment of special committee to explore strategic alternatives.
    Immutep Limited (NASDAQ: IMMP) shares climbed 12.95 percent to close at $2.53.
    xG Technology, Inc. (NASDAQ: XGTI) rose 12.64 percent to close at $0.8561 after the company&rsq

Top 5 Clean Energy Stocks To Own For 2019: Frontline Ltd.(FRO)

Advisors’ Opinion:

  • [By Logan Wallace]

    Pyxis Tankers (NASDAQ: PXS) and Frontline (NYSE:FRO) are both small-cap transportation companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.

  • [By Asit Sharma]

    Last year, net income dropped from $146.4 million to $101.2 million, creating the sharp trend line seen above. The 2017 earnings dip can be traced to numerous factors, including higher interest expense, a reduction in tanker income, fewer ships in the fleet on charter to former parent Frontline Shipping (NYSE:FRO), and the bankruptcy filing of Seadrill Ltd. (NYSE:SDRL). Seadrill’s reorganization has impacted Ship Finance’s offshore revenue, as it has three out of four offshore drilling rigs on charter to affiliates of Seadrill.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Frontline (FRO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Matthew DiLallo]

    Shares of Frontline Ltd.(NYSE:FRO) surged more than 13% by 10:00 a.m. EDT on Thursday after the oil tanker company posted better-than-expected first-quarter results.

  • [By Lisa Levin] Gainers
    Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) jumped 124.8 percent to $243.725 in reaction to an encouraging Phase 2 clinical trial update. The clinical-stage biopharmaceutical company said its liver-directed, thyroid hormone receptor called MGL-3196 showed a statistical significance in the primary endpoint of lowering liver fat at 12 weeks and also 36 weeks.
    Viking Therapeutics, Inc. (NASDAQ: VKTX) gained 63.4 percent to $8.12 after falling 4.42 percent on Wednesday.
    Takung Art Co., Ltd. (NYSE: TKAT) rose 43.3 percent to $2.9094
    vTv Therapeutics Inc. (NASDAQ: VTVT) shares climbed 29.7 percent to $2.16 after the company reported a licensing deal with Newsoara Biopharma to rights for vTv's PDE4 Inhibitor in China and other Pacific Rim territories.
    Akers Biosciences, Inc. (NASDAQ: AKER) gained 26.2 percent to $0.4109. The developer of rapid health information technologies said Wednesday afternoon it was granted a 180-day extension from the Nasdaq Stock Market to meet the requirement of a minimum $1.00 per share closing bid price for 10 straight days.
    Genprex, Inc. (NASDAQ: GNPX) rose 22.2 percent to $11.6254. Genprex reported engagement of WIRB-Copernicus Group to provide clinical trial services to support Oncoprex clinical trial program.
    J.Jill, Inc. (NYSE: JILL) gained 21 percent to $7.506 after the company posted upbeat quarterly earnings.
    Urban One, Inc. (NASDAQ: UONE) gained 19.7 percent to $3.95 after rising 78.38 percent on Wednesday.
    TapImmune, Inc. (NASDAQ: TPIV) shares gained 18.5 percent to $6.03 after climbing 24.15 percent on Wednesday.
    Kirkland's, Inc. (NASDAQ: KIRK) rose 17.3 percent to $12.95 after reporting upbeat Q1 results.
    CymaBay Therapeutics, Inc. (NASDAQ: CBAY) shares gained 15.1 percent to $13.210.
    The Brink's Company (NYSE: BCO) climbed 14.2 percent to $77.875 as the company announced plans to acquire Dunbar Armored for $520 million in cash.
    Keysight Technologies, Inc. (NYSE: KEY
  • [By ]

    What Happened
    Shares of Frontline Ltd. (NYSE:FRO) surged more than 13% by 10:00 a.m. EDT on Thursday after the oil tanker company posted better-than-expected first-quarter results.

Top 5 Clean Energy Stocks To Own For 2019: LivePerson Inc.(LPSN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    LivePerson (NASDAQ:LPSN) released its quarterly earnings results on Thursday. The technology company reported $0.01 EPS for the quarter, Bloomberg Earnings reports. LivePerson had a negative return on equity of 2.93% and a negative net margin of 6.95%. The company had revenue of $58.24 million for the quarter, compared to analysts’ expectations of $57.22 million. During the same period in the prior year, the firm earned $0.01 earnings per share. The firm’s revenue was up 14.4% compared to the same quarter last year. LivePerson updated its Q2 guidance to $0.00-0.01 EPS and its FY18 guidance to $0.11-0.15 EPS.

  • [By Logan Wallace]

    LivePerson, Inc. (NASDAQ:LPSN) SVP Daryl Carlough sold 425 shares of the company’s stock in a transaction dated Wednesday, June 20th. The shares were sold at an average price of $23.80, for a total value of $10,115.00. Following the completion of the sale, the senior vice president now directly owns 14,647 shares of the company’s stock, valued at $348,598.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Logan Wallace]

    Mobileye (OTCMKTS: MBBYF) and LivePerson (NASDAQ:LPSN) are both computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

  • [By Shane Hupp]

    LivePerson (NASDAQ:LPSN) updated its FY18 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $0.11-0.15 for the period, compared to the Thomson Reuters consensus estimate of $0.09. The company issued revenue guidance of $239-243 million, compared to the consensus revenue estimate of $239.45 million.LivePerson also updated its Q2 guidance to $0.00-0.01 EPS.

  • [By Rick Munarriz]

    Double-digit growth is back at LivePerson (NASDAQ:LPSN). The provider of high-tech customer support reported fresh financials after Thursday’s market close, delivering its best period of year-over-year revenue growth in nearly three years.